



**EPIC™ MITRAL STENTED TISSUE VALVE  
WITH LINX™ AC TECHNOLOGY**

# EPIC. BY DESIGN.

Engineered to deliver excellent durability,  
along with smooth implantability  
and outstanding performance.

Information contained herein for **DISTRIBUTION in Europe, Middle-East and Africa ONLY.**  
Check the regulatory status of the device in areas where CE marking is not the regulation in force.

  
**Abbott**

# EPIC IMPLANTABILITY


The excellent implantability features of the Epic™ Mitral valve enable surgeons to customize their implantation strategy based upon patient needs, helping minimize implant related complications.

## THE LOWEST PROTRUSION FOR OPTIMAL IMPLANTABILITY.

Epic Mitral has the lowest overall ventricular protrusion in all valve sizes, making it an exceptional valve for the mitral position. A symmetrical, low profile design:

- Reduces the risk of LV outflow tract obstruction<sup>1</sup>
- Eliminates the need for a specific orientation during implantation
- Makes the valve easier to implant in minimally invasive surgery (MIS)

## VENTRICULAR PROTRUSION\*



## THE INNOVATIVE FLEXFIT™ SYSTEM FOR A CUSTOMIZABLE IMPLANTATION.

- Soft Sewing Cuff**  
Provides limited suture drag and parachuting forces
- Symmetrical Triple Composite Design**  
Eliminates septal muscle bar leaflet and need for orientation
- Unique Pericardial Shield**  
Provides a tissue-to-tissue interface to help prevent the risk of abrasion
- Flexible Polymer Stent**  
Facilitates placing knots and maneuverability in implantation
- Ratcheting Holder**  
Mitigates potential for suture looping
- Rinse Time of 2 x 10 Seconds**  
Allows for abbreviated procedure prep time

\* For 27mm valve size, measured from the furthest point from the cuff.

Information contained herein for **DISTRIBUTION in Europe, Middle-East and Africa ONLY**. Check the regulatory status of the device in areas where CE marking is not the regulation in force.

## EPIC PERFORMANCE

The Epic™ Mitral valve achieves minimal valvular regurgitation by providing excellent paravalvular cuff sealing and impressive central leaflet coaptation, both crucial in the mitral position.

### DESIGNED FOR THE CHALLENGES OF THE MITRAL POSITION.

- Innovative Triple Composite Design uses three separate porcine leaflets to optimize leaflet coaptation, reduce stress, and mitigate regurgitation
- The easily conforming sewing cuff minimizes regurgitation in high risk anatomies, such as mitral annular calcification



Information contained herein for **DISTRIBUTION in Europe, Middle-East and Africa ONLY**.  
Check the regulatory status of the device in areas where CE marking is not the regulation in force.

### OUTSTANDING PERFORMANCE.7



**100%**

**FREEDOM** from  
ALL bleeding events\*



**97.3%**

**FREEDOM** from  
stroke events\*


\*From standalone Mitral valve replacement.



# EPIC DURABILITY

The Epic™ valve is identical in design to the Biocor™ valve, which has proven 20-year durability and more than 35 years of clinical experience.<sup>8-11\*</sup>

## PROVEN DESIGN FOR LONG-TERM DURABILITY



## BUILDING ON BIOCOR'S SUCCESS.


In animal studies, the Linx AC treatment\*\* has demonstrated resistance to calcification in four ways:



- EXTRACTS LIPIDS<sup>12</sup>
- REDUCES FREE ALDEHYDES<sup>13,14</sup>
- MINIMIZES CHOLESTEROL UPTAKE<sup>15</sup>
- STABILIZES LEAFLET COLLAGEN<sup>15</sup>

## EXCEPTIONAL DURABILITY.

Freedom from Structural Valve Deterioration (SVD)<sup>10</sup>:




**Epic™ Mitral**  
At 10 years; all patient ages

## AT ALL AGES.


Actuarial Freedom from Reoperation Due to SVD<sup>8-9, 11\*</sup>:

### AGE AT IMPLANT


≥65



**Biocor™**




**PERIMOUNT™**




**Hancock™ II**


<65



**Biocor™**



**PERIMOUNT™**



**Hancock™ II**

At 15 Years

\*Based on available 10+ and 20+ year retrospective studies.

\*\*There is no clinical data currently available that evaluates the long-term impact of anticalcification tissue treatment in humans.


\*Results from different clinical trials are not directly comparable. Information provided for educational purposes only.

\*\*Interpolated from Borger data, Figure 5

Information contained herein for **DISTRIBUTION in Europe, Middle-East and Africa ONLY**. Check the regulatory status of the device in areas where CE marking is not the regulation in force.

# EPIC™ MITRAL VALVE SYSTEM

Model Number	Valve Size (mm)	Tissue Annulus Diameter (mm)	Internal Diameter (Stent ID mm)	Ventricular Protrusion (mm)	Total Height (mm)
E100-25M-00	25	25	23	9	16
E100-27M-00	27	27	25	9	17
E100-29M-00	29	29	27	10	19
E100-31M-00	31	31	29	10	20
E100-33M-00	33	33	31	11	20



## Valve Storage Information

### Recommendations

Storage Temperature: 5°–25° C (41°–77° F)  
 Storage Solution: 0.5% formaldehyde solution  
 Resterilization: Epic valves must not be resterilized  
 Shelf Life: Four years  
 Radiopaque Marker for X-ray: A stainless steel wire located under the sewing cuff allows the valve to be seen under X-ray

## Accessories

Model Number	Description
B1000	Bioprosthetic Heart Valve Sizer Set One (1) click-in holder handle Six (6) double-ended aortic/Supra sizers (19, 21, 23, 25, 27, 29) Five (5) mitral sizers (25, 27, 29, 31, 33) One (1) autoclavable tray for storage of components One (1) autoclavable tray cover
B1000-H	Replacement Handle One (1) click-in holder handle

### REFERENCES

- Guler, N., Ozkara, C., Akyol, A., Left Ventricular Outflow Tract Obstruction after Bioprosthetic Mitral Valve Replacement with Posterior Mitral Leaflet Preservation. *Texas Heart Institute Journal*. 2006; 33:399-401.
- Epic IFU.
- Carpentier-Edwards PERIMOUNT THEON Mitral Replacement System Brochure. #AR00856.
- Edwards PERIMOUNT Magna Mitral Pericardial Bioprosthesis Brochure. #AR01603.
- Medtronic Mosaic Bioprosthesis Aortic and Mitral Brochure. #UC200103933b EN.
- Medtronic Hancock II and Hancock II Ultra Bioprosthesis Brochure.
- Lehmann S, et al. Mid-Term Results after Epic™ Xenograft Implantation for Aortic, Mitral, and Double Valve Replacement. *Journal of Heart Valve Disease*. 2007; 16:641-648.
- Mykén, P. S., & Bech-Hansen, O. A 20-year experience of 1712 patients with the Biocor porcine bioprosthesis. *Journal of Thoracic and Cardiovascular Surgery*. 2009; 137(1), 76-81.
- Bourguignon, T., Bouquiaux-Stablo, A. L., Loardi, C., Mirza, A., Candolfi, P., Marchand, M., & Aupart, M. R. (2014). Very late outcomes for mitral valve replacement with the Carpentier-Edwards pericardial bioprosthesis: 25-year follow-up of 450 implantations. *Journal of Thoracic and Cardiovascular Surgery*, 148, 2004-2011.
- Lehmann S, Jawad K, Meyer A, Fischer J, Feder S, Misfeld M, Garbade J. Long-term follow-up after porcine xenograft mitral valve replacement. Presented at: 2017 American Association For Thoracic Surgery Mitral Conclave. April 27-28, 2017; New York, NY USA.
- Borger, M. A., Ivanov, J., Armstrong, S., Christie-Hrybinsky, D., Feindel, C. M., & David, T. E. (2006). Twenty-year results of the Hancock II bioprosthesis. *The Journal of Heart Valve Disease*, 15, 49-56.
- Vyavahare, N., Hirsch, D., Lerner, E., et al. Prevention of bioprosthetic heart valve calcification by ethanol preincubation. *Circulation*, 1997;95:479-488.
- Frater, R. W. M., Seifert, E., Liao, K., et al. (1997). Advances in Anticalcific and Antidegenerative Treatment of Heart Valve Bioprostheses. First Edition, edited by Gabbay, S., & Wheatley, DJ. Silent Partners, Inc. 1997;9:105-113.
- Kelly, SJ, Ogle, MF, Carlyle, WC, et al. Biocompatibility and Calcification of Bioprosthetic Heart Valves. Society for Biomaterials, Sixth World Biomaterials Congress Transaction, 2000:13534.
- Vyavahare, N., Hirsch, D., Lerner, E., et al. Prevention of calcification of glutaraldehyde-crosslinked porcine aortic cusps by ethanol preincubation: Mechanistic studies of protein structure and water-biomaterial relationships. *J Biomed Mater Res*. 1998; 40:577-585.

**CAUTION:** This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at [efu.abbottvascular.com](http://efu.abbottvascular.com) or at [medical.abbott/manuals](http://medical.abbott/manuals) for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.  
 Photo(s) on file at Abbott. Information contained herein is for distribution for Europe, Middle East and Africa ONLY. Please check the regulatory status of the device before distribution in areas where CE marking is not the regulation in force.

**Abbott International BVBA**  
 Park Lane, Culliganlaan 2B, B-1831 Diegem, Belgium, Tel: +32 2 714 14 11  
 For more information, visit our website at [www.abbott.com](http://www.abbott.com)  
 © 2018 Abbott. All Rights Reserved. 9-EH-1-8642-01 10-2018

